Smart wire could reveal clot secrets during stroke treatment

NCT ID NCT04993079

Completed Knowledge-focused Sponsor: Sensome Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This first-in-human study tested a new smart guidewire (Clotild®) in 45 stroke patients undergoing emergency clot removal. The wire helps guide the removal tool and also measures the clot's electrical properties to determine its composition. The main goal was to check safety, such as whether the wire causes blood vessel damage, and to see if it can accurately tell what the clot is made of.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clotild® Smart Guidewire System (a device used to guide clot removal tools and measure clot characteristics)
What this could lead to: If successful, this device could help doctors better understand clot composition during stroke treatment, potentially improving future clot removal procedures.
What could go wrong: This is a very early, small study focused on safety and feasibility. The device may not provide useful measurements or could cause vessel injury. Results may not apply to all stroke patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STROKE

Contacts and locations

Locations

CHU Limoges

Limoges, 87000, France
Gold Coast University Hospital

Southport, Queensland, QL 5215, Australia
Liverpool Hospital

Liverpool, New South Wales, NSW 2170, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.